Real-world data reveal varying efficacy of CDK4/6 inhibitors in HR+/HER2- aBC, supporting personalized treatment choices. New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy. A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication. Palbociclib rechallenge did not significantly improve PFS in HR+/HER2- advanced breast cancer, PALMIRA trial finds. iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials. Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer. Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations. The study used SEER data of nearly 20,000 cases. People diagnosed with metastatic breast cancer have a notably increased risk of developing heart disease. The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease. New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy. The Breast Cancer Index assists in decision-making regarding adjuvant endocrine therapy for hormone receptor-positive BC. Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer. Dr. Margaret Gatti-Mays details the treatment options for BC patients in the hormone receptor-positive metastatic setting. The Oncology Brothers spoke with Dr. Margaret Gatti-Mays, who provided invaluable insights on hormone receptor-positive BC. Patients ≥70 years of age were more likely to have a reduction in their palbociclib dosage. The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer. The Oncology Brothers talk with Paolo Tarantino, MD, about the TROPiCS-02 study presented at SABCS. Results from the 21-gene Breast Recurrence Score commercial assay were successful predictors for cancer-specific mortality.